Vaccine therapy for prostate cancer.
Vaccine therapy may provide an alternative for prostate cancer patients whose disease no longer responds to hormone therapy. Administration of dendritic cells pulsed with prostate-specific membrane antigen (PSMA) induces cellular immune responses against the tumor with virtually no adverse effects. About 30% of the evaluable patients were identified as partial responders, based on the National Prostate Cancer Project (NPCP) criteria. In addition, there was a 50% decrease of serum prostate-specific antigen or resolution of previously measurable lesions on imaging. Dendritic cell vaccine therapy may have a synergistic effect, when combined with other therapies.
Tjoa
B A
BA
Cancer Research Division, Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, Washington, USA.
Elgamal
A A
AA
Murphy
G P
GP
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy*
D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen